miR-622 contributes to the suppression of drug resistance in sorafenib-resistant HCC cells by targeting KRAS and inhibiting RAF/ERK and PI3K/Akt signaling [177]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.